Nitroglycerin for Esophageal Food Impaction: A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase 2 Clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503983-17-00

Acronym

MK2021

Enrollment

Registered

2023-08-28

Start date

2025-06-12

Completion date

Unknown

Last updated

2025-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Food Impaction

Brief summary

• The number of patients with resolution of EFI without the need of endoscopic removal when treated with nitroglycerin (NGT) compared to the number of patients with resolution of EFI when treated with placebo.

Interventions

DRUGPlacebo

DRUGPlacebo 6 mm convex. White

DRUGround and normal convex tablets. Size 6 mm. The placebo is developed at the Capital Region Pharmacy in Denmark. The formulation is identical with a marketed SAD tablet but without active ingredient. Therefore no specific documentation for the pharmaceutical development is made.

DRUGNitroglycerin "DAK"

DRUGsublinguale resoribletter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• The number of patients with resolution of EFI without the need of endoscopic removal when treated with nitroglycerin (NGT) compared to the number of patients with resolution of EFI when treated with placebo.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026